| |
|
|
|
|
| |
 |
Clontech Laboratories & TET Systems Announce the Broadening of Their Li |
 |
|
And the Upcoming Launch of The New Tet-On® 3G™ Inducible Expression System |
|
|
|
|
|
| |
 |
Cerenis Therapeutics and Novasep awarded EUR 10.7 million |
 |
|
Awarded from the French Government for the development of CER-001, an HDL mimetic |
|
|
|
|
|
| |
 |
Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus |
 |
|
Rottapharm Madaus has signed a drug discovery research contract with Selvita, Poland based product and solution provider |
|
|
|
|
|
| |
 |
Actelion obtains option to acquire privately-held Trophos |
 |
|
Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 |
|
|
|
|
|
| |
 |
EyeTechCare raises EUR 7.5 million in a second funding round |
 |
|
These will enable the company to complete the clinical trial of EyeOP1, a medical device for the treatment of glaucoma |
|
|
|
|
|
| |
 |
Hybrigenics SA brings its fee-for-service activities to a fully owned subsi |
 |
|
Its fee-for-service scientific activities are brought to a fully-owned subsidiary named Hybrigenics Services SAS |
|
|
|
|
|
| |
 |
MorphoSys announces clinical milestone from strategic alliance |
 |
|
Second clinical milestone in 2010 |
|
|
|
|
|
| |
 |
Increased demand drives Queensland Compound Library Expansion |
 |
|
QCL capacity is increased by the acquisition of a fourth additional comPOUND® storage module |
|
|
|
|
|
| |
 |
LSP Announces Acquisition of Portfolio Company FlowCardia, Inc. |
 |
|
Bard is worldwide leader in products that focus on disease state management in three key areas: vascular, urology and oncology |
|
|
|
|
|
| |
 |
Vaxon Biotech successfully completes its Phase I/II trial of Vx-001 |
 |
|
Results show Vx-001 cancer vaccine to be safe, strongly immunogenic and clinically active |
|
|
|
|
|
| |
 |
New clean-room production of ophthalmic systems at Aptar Pharma's |
 |
|
Located at Aptar Pharma's Eigeltingen plant in Germany |
|
|
|
|
|
| |
 |
PharmaMar presents new trials with three marine-based drugs |
 |
|
The trials provide new information on the drugs' action mechanisms and antitumour potential |
|
|
|
|
1 2 3 Siguiente > |
|